News

Predictive Model in Multiple Myeloma: Focus on Pyroptosis-Related Genes

KarMMa-3 Trial Update: Use of Idecabtagene Vicleucel in Resistant Multiple Myeloma

Extended Genetic Profiling May Improve Risk Prediction in Transplant-Eligible Patients With Myeloma

Does the Addition of Upfront Autologous HSCT Improve Outcomes in Patients With Multiple Myeloma?

Novel SK2 Inhibitor Under Study in Resistant Multiple Myeloma

18-Month Follow-up on Ciltacabtagene Autoleucel in Patients With Multiple Myeloma

Comparison of Standard Therapies for Transplantation-Ineligible Patients With Myeloma

Potential Genomic Mechanisms of Resistance to Targeted Immunotherapy for Myeloma

Salvage Therapies After Myeloma Progression on CAR T-Cell Therapy

CAR T-Cell Therapy After BCMA-Targeted Therapy for Resistant Multiple Myeloma

Immunologic Profile of Patients With High-Risk Smoldering Myeloma

Extended Consolidation Therapy After ASCT for Ultra–High-Risk Multiple Myeloma

Large Single-Cell RNA-Sequencing Cohort Sheds Light on Precursor Conditions to Multiple Myeloma

Updated Results From Cohort C of CARTITUDE-2: Ciltacabtagene Autoleucel for Progressive Multiple Myeloma

Subcutaneous, On-Body Delivery of Isatuximab-irfc for Resistant Multiple Myeloma

Dose-Expansion Results of Mezigdomide-Based Therapy for Advanced Multiple Myeloma

Cohort 2C of KarMMa-2: Idecabtagene Vicleucel for High-Risk Multiple Myeloma

What Is the Optimal Duration of Lenalidomide Maintenance Therapy After ASCT?

BCMA/CD19 Dual-Targeting CAR T-Cell Therapy for Multiple Myeloma

Use of Bortezomib and Lenalidomide in Conjunction With ASCT in Myeloma

Tocilizumab Pretreatment Followed by Cevostamab for Resistant Myeloma

ASH 2022: Quadruplet Regimen Under Study in High-Risk Smoldering Multiple Myeloma

ASH 2022: Dose-Escalation Study Evaluates T-Cell–Engaging Bispecific Antibody in Resistant Myeloma

ASH 2022: Influence of Microenvironment Changes on Achieving Sustained Remission in Myeloma

ASH 2022: Does KDM6A Expression Modulate the Efficacy of Daratumumab in Myeloma?

ASH 2022: Dexamethasone-Sparing Regimen for Elderly Patients With Multiple Myeloma

ASH 2022: Bispecific Antibody Elranatamab in Patients Under Study in Aggressive Multiple Myeloma

ASH 2022: Can Intensive Treatment Regimen Reduce the Risk of Disease Progression in Smoldering Myeloma?

ASH 2022: First-in-Human Study of Modakafusp Alfa in Resistant Multiple Myeloma

ASH 2022: Phase I/II Results of CD3 Bispecific Antibody in Resistant Multiple Myeloma

ASH 2022: Early-Phase Trial Evaluates Elranatamab in Resistant Multiple Myeloma

Photon-Counting Detector CT May Improve the Visibility of Multiple Myeloma Lesions

Exploring the Use of Translationally Controlled Proteins in the Treatment of Multiple Myeloma

Sequential Combinations of Different T-Cell Redirection Therapies in Resistant Myeloma

SITC 2022: Cellular Research May Lead to the Next Generation of Therapies for Myeloma

Should Routine Stem Cell Transplantation Be Discontinued in Newly Diagnosed Patients With Myeloma?

SITC 2022: Antigen-Specific Memory CD8-Positive T Cells Target BCMA to Treat Multiple Myeloma

ASTRO 2022: CNS-Directed Radiotherapy for Patients With Extramedullary Multiple Myeloma

ASTRO 2022: Can Radiotherapy Prevent Progression to Myeloma in Patients With Plasmacytomas?

FDA Brief: Bispecific Antibody Receives Breakthrough Therapy Designation in Resistant Myeloma

SLAMF7 Antigen and Myeloma: Therapeutic Target for Antibody-Based and Cellular Immunotherapy?

Daratumumab-Based Chemoimmunotherapy for Multiple Myeloma: Focus on Advanced Renal Failure

ASTRO 2022: Community-Based Registry Offers Glimpse at Use of Radiotherapy for Myeloma

FDA Brief: Teclistamab-cqyv Granted Accelerated Approval in Resistant Myeloma

CD38-CAR Natural Killer Cells: Potential Immunotherapy Target in Multiple Myeloma?

SOHO 2022: Exploring the Role of Salvage Autologous HCT in Myeloma

Gut Microbiota and Gastrointestinal Toxicity From Proteasome Inhibitors in Myeloma

Early-Phase Research on Sotatercept in Combination Therapy for Resistant Multiple Myeloma

SOHO 2022: Update From CARTITUDE-2 of Ciltacabtagene Autoleucel in Multiple Myeloma

Can a Mutational Signature Predict Outcomes With Carfilzomib-Based Therapy for Myeloma?

ASCO Quality 2022: Underrepresentation of Black Patients in Multiple Myeloma Clinical Trials

BCMA-Targeted CAR T-Cell Therapy for Older Patients With Multiple Myeloma

Are Baseline Ocular Conditions Affected by Belantamab Mafodotin Treatment in Myeloma?

Red Cell Distribution Width: A Prognostic Indicator in Newly Diagnosed Multiple Myeloma?